SANDOSTATIN IN THE TREATMENT OF ACROMEGALY

善得定治疗肢端肥大症

• 批准号: 3887167
• 负责人: MARY LEE VANCE
• 金额: --
• 依托单位: UNIVERSITY OF VIRGINIA
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3887167
• 关键词: acromegaly; clinical trials; human subject; human therapy evaluation; insulinlike growth factor; somatostatin

Sandostatin, an analog of somatostatin, will reduce serum growth hormone and insulin-like growth factor-I concentrations and effect clinical improvement in acromegalic patients when compared with placebo treatment.

生长抑素的类似物善得定将降低血清生长激素 胰岛素样生长因子-I的浓度及对临床的影响 肢端肥大症患者与安慰剂治疗相比的改善。